Two Sigma Investments LP Has $533,000 Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Two Sigma Investments LP raised its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 226.1% during the 4th quarter, HoldingsChannel reports. The firm owned 33,664 shares of the company’s stock after purchasing an additional 23,342 shares during the quarter. Two Sigma Investments LP’s holdings in Keros Therapeutics were worth $533,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in Keros Therapeutics by 585.9% during the fourth quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company’s stock valued at $3,379,000 after purchasing an additional 182,314 shares during the last quarter. Darwin Global Management Ltd. grew its holdings in Keros Therapeutics by 10.7% during the fourth quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company’s stock valued at $26,707,000 after purchasing an additional 163,403 shares during the last quarter. Barclays PLC grew its holdings in Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Norges Bank acquired a new position in Keros Therapeutics during the fourth quarter valued at approximately $1,027,000. Finally, BNP Paribas Financial Markets acquired a new position in Keros Therapeutics during the fourth quarter valued at approximately $730,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Insider Transactions at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the firm’s stock in a transaction that occurred on Wednesday, April 9th. The shares were bought at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the transaction, the insider now owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 20.60% of the company’s stock.

Keros Therapeutics Trading Down 0.5%

NASDAQ KROS opened at $15.04 on Monday. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37. The stock has a 50 day moving average of $13.44 and a 200-day moving average of $17.76. The company has a market cap of $610.85 million, a PE ratio of -2.89 and a beta of 1.31.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $211.25 million during the quarter, compared to the consensus estimate of $84.62 million. During the same quarter last year, the firm posted ($1.21) EPS. As a group, sell-side analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on KROS shares. Truist Financial lowered their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, April 9th. HC Wainwright lowered their price objective on shares of Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Scotiabank lowered their price objective on shares of Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating on the stock in a research note on Monday, May 12th. Wedbush restated a “neutral” rating and issued a $15.00 price objective on shares of Keros Therapeutics in a research note on Friday, May 30th. Finally, Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Keros Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $37.00.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.